Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.

Jayasena CN, Nijher GM, Chaudhri OB, Murphy KG, Ranger A, Lim A, Patel D, Mehta A, Todd C, Ramachandran R, Salem V, Stamp GW and 4 more

Show all authors

Donaldson M, Ghatei MA, Bloom SR, Dhillo WS

The Journal of clinical endocrinology and metabolism9 Oct 2009Cited by 149 (Europe PMC)

PMID19820030DOI10.1210/jc.2009-0406PepBankPUB-19820030

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with hypothalamic amenorrhea, the first subcutaneous kisspeptin injection raised serum LH.
In plain wordsIn women with hypothalamic amenorrhea, the first kisspeptin injection clearly raised LH.
Peptide
Kisspeptin-54 (metastin)
Outcome
IncreaseLH increase after first kisspeptin injection
Study
n = 5
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
6.4 nmol/kg · subcutaneousAs given in this study (human).
Measurements
Mean maximal LH increment from baseline within 4 h
24 IU/liter
day 1
Source sentences
Summary
On the first injection day, potent increases in serum LH and FSH were observed after sc kisspeptin injection in women with HA (mean maximal increment from baseline within 4 h after injection: LH, 24.0 +/- 3.5 IU/liter
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prospective, randomized, double-blinded, parallel design study.
Summary · context
Women with HA received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline (n = 5 per group) for 2 wk.
Report a problemFND-1982003001
02HumanRandomized controlled trialEfficacy outcome
In women with hypothalamic amenorrhea, the first subcutaneous kisspeptin injection raised serum FSH.
In plain wordsIn women with hypothalamic amenorrhea, the first kisspeptin injection clearly raised FSH.
Peptide
Kisspeptin-54 (metastin)
Outcome
IncreaseFSH increase after first kisspeptin injection
Study
n = 5
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
6.4 nmol/kg · subcutaneousAs given in this study (human).
Measurements
Mean maximal FSH increment from baseline within 4 h
9.1 IU/liter
day 1
Source sentences
Summary
On the first injection day, potent increases in serum LH and FSH were observed after sc kisspeptin injection in women with HA (mean maximal increment from baseline within 4 h after injection: LH, 24.0 +/- 3.5 IU/liter; FSH, 9.1 +/- 2.5 IU/liter).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prospective, randomized, double-blinded, parallel design study.
Summary · context
Women with HA received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline (n = 5 per group) for 2 wk.
Report a problemFND-1982003002
03HumanRandomized controlled trialEfficacy outcome
In women with hypothalamic amenorrhea, the LH response to kisspeptin was significantly smaller on the 14th injection day than on the first.
In plain wordsIn women with hypothalamic amenorrhea, the LH response to kisspeptin was much smaller after 2 weeks of injections.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseLH response on day 14 versus day 1
Study
n = 5
Comparator
First injection day
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
6.4 nmol/kg · subcutaneous · 2 wkAs given in this study (human).
Measurements
Mean maximal LH increment from baseline within 4 h
2.5 IU/liter
day 14
Source sentences
Summary
These responses were significantly reduced on the 14th injection day (mean maximal increment from baseline within 4 h postinjection: LH, 2.5 +/- 2.2 IU/liter, P < 0.05; FSH, 0.5 +/- 0.5 IU/liter, P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prospective, randomized, double-blinded, parallel design study.
Summary · context
Women with HA received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline (n = 5 per group) for 2 wk.
Report a problemFND-1982003003
04HumanRandomized controlled trialEfficacy outcome
In women with hypothalamic amenorrhea, the FSH response to kisspeptin was significantly smaller on the 14th injection day than on the first.
In plain wordsIn women with hypothalamic amenorrhea, the FSH response to kisspeptin was much smaller after 2 weeks of injections.
Peptide
Kisspeptin-54 (metastin)
Outcome
DecreaseFSH response on day 14 versus day 1
Study
n = 5
Comparator
First injection day
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
6.4 nmol/kg · subcutaneous · 2 wkAs given in this study (human).
Measurements
Mean maximal FSH increment from baseline within 4 h
0.5 IU/liter
day 14
Source sentences
Summary
These responses were significantly reduced on the 14th injection day (mean maximal increment from baseline within 4 h postinjection: LH, 2.5 +/- 2.2 IU/liter, P < 0.05; FSH, 0.5 +/- 0.5 IU/liter, P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prospective, randomized, double-blinded, parallel design study.
Summary · context
Women with HA received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline (n = 5 per group) for 2 wk.
Report a problemFND-1982003004
05HumanRandomized controlled trialMechanism
In women with hypothalamic amenorrhea, subjects remained responsive to GnRH after 2 weeks of kisspeptin treatment.
In plain wordsIn women with hypothalamic amenorrhea, the body still responded to GnRH after kisspeptin treatment.
Peptide
Kisspeptin-54 (metastin)
Outcome
No significant changeGnRH responsiveness after kisspeptin treatment
Study
n = 5
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
6.4 nmol/kg · subcutaneous · 2 wkAs given in this study (human).
Source sentences
Summary
Subjects remained responsive to GnRH after kisspeptin treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prospective, randomized, double-blinded, parallel design study.
Summary · context
Women with HA received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline (n = 5 per group) for 2 wk.
Report a problemFND-1982003005
06HumanRandomized controlled trialEfficacy outcome
In women with hypothalamic amenorrhea, kisspeptin treatment caused no significant change in LH pulsatility.
In plain wordsIn women with hypothalamic amenorrhea, kisspeptin treatment did not change LH pulses.
Peptide
Kisspeptin-54 (metastin)
Outcome
No significant changeLH pulsatility
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
6.4 nmol/kg · subcutaneous · 2 wkAs given in this study (human).
Source sentences
Summary
No significant changes in LH pulsatility or ultrasound measurements of reproductive activity were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prospective, randomized, double-blinded, parallel design study.
Summary · context
Women with HA received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline (n = 5 per group) for 2 wk.
Report a problemFND-1982003006
07HumanRandomized controlled trialEfficacy outcome
In women with hypothalamic amenorrhea, kisspeptin treatment caused no significant change in ultrasound measurements of reproductive activity.
In plain wordsIn women with hypothalamic amenorrhea, kisspeptin treatment did not change ultrasound signs of reproductive activity.
Peptide
Kisspeptin-54 (metastin)
Outcome
No significant changeUltrasound measurements of reproductive activity
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
6.4 nmol/kg · subcutaneous · 2 wkAs given in this study (human).
Source sentences
Summary
No significant changes in LH pulsatility or ultrasound measurements of reproductive activity were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prospective, randomized, double-blinded, parallel design study.
Summary · context
Women with HA received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline (n = 5 per group) for 2 wk.
Report a problemFND-1982003007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT03286517

Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.

Ghulam Nabin = 3026 Jun 2014 to 5 Mar 2015

Reproductive Physiological Phenomena

Trial page ClinicalTrials.govUpdated 18 Sept 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.